NASDAQ · Medical - Devices

ClearPoint Neuro Inc. (CLPT) Stock

$10.48 -0.10% NASDAQ: CLPT Healthcare

Valuation

MetricValue
Price$10.48
Market Cap$314.29M
P/E Ratio-12.57
P/B Ratio41.09
P/S Ratio10.52
EPS (TTM)$0.00
52-Week High$30.10
52-Week Low$8.27
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-188.09%
ROA-39.85%
ROCE-40.62%
Gross Margin-64.86%
Operating Margin-64.86%
Net Margin-81.76%
Debt/Equity5.93
Current Ratio5.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$16.0M$21.0M$24.0M$31.0M$37.0M
Operating Profit$-13.0M$-16.0M$-22.0M$-20.0M$-24.0M
Net Profit$-14.0M$-16.0M$-22.0M$-19.0M$-26.0M
EPS$-0.69$-0.68$-0.90$-0.70$-0.90
Op Margin-82.0%-79.5%-93.7%-62.9%-65.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$66.0M$55.0M$43.0M$39.0M$98.0M
Total Liabilities$17.0M$19.0M$21.0M$14.0M$70.0M
Cash$54.0M$28.0M$23.0M$20.0M$46.0M
Borrowings$12.0M$12.0M$14.0M$4.0M$58.0M

Latest News

Clearpoint Neuro Insider Sold Shares Worth $387,600, According to a Recent SEC Filing MT Newswires · Jul 2, 2026 ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains? Zacks · Jun 18, 2026 ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value InvestorsHub · Jun 17, 2026 ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint ACCESS Newswire · May 27, 2026 How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risks Simply Wall St. · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-16.0M$-14.0M$-9.0M$-24.0M
Investing Cash Flow$0$-11.0M$8.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$-2.0M
Net Cash Flow$34.0M$-26.0M$-4.0M$-3.0M$27.0M
Free Cash Flow$-13.0M$-16.0M$-14.0M$-9.0M$-24.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.36
EV / EBITDA-17.48
FCF Yield-7.04%
Quick Ratio3.87
Interest Coverage-7.68
Return 1Y25.13%
Return 3Y113.72%
Return 5Y-4.60%

Ownership

Insiders Held5.48%
Institutions Held50.62%
Institutions Float Held53.55%
Institutional HolderSharesReport Date
Blackrock Inc.2,082,7502026-03-31
MAK Capital One LLC1,901,4892026-03-31
Vanguard Capital Management LLC1,243,6152026-03-31
Geode Capital Management, LLC705,7202026-03-31
State Street Corporation679,8192026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKBAAkebia Therapeutics, Inc. $0.80 -1.68% -8.01 $214.90M 0.00%
AVNS $24.99 +0.04% 19.96 $1.17B 0.00%
CMPSCOMPASS Pathways plc $13.31 -0.60% -6.19 $1.28B 0.00%
CTKBCytek Biosciences, Inc. $5.43 +1.31% -9.42 $701.24M 0.00%
LABStandard BioTools Inc. $0.69 +2.85% -3.23 $269.87M 0.00%

About ClearPoint Neuro Inc.

ClearPoint Neuro Inc. is led by CEO Joseph Michael Burnett, employs 115 people, headquartered in US, publicly traded since 2012.

ClearPoint Neuro Inc. (CLPT) stock trades at $10.48 with a market capitalization of $314.29M. The stock is valued at a price-to-earnings (P/E) ratio of -12.57, price-to-book of 41.09, price-to-sales of 10.52. Over the past 52 weeks the stock has ranged between $8.27 and $30.10, and currently trades 65.2% below its 52-week high.

On profitability, ClearPoint Neuro Inc. generates a return on equity (ROE) of -188.09%, return on capital employed of -40.62%, an operating margin of -64.86%, a net profit margin of -81.76%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides